Cargando…

Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program

The death rate from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in 2022 was lower than the death rate in 2021, when the infection rate increased. Hybrid immunity provided by a combination of vaccination and infection, including asymptomatic infection, may confer effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Chevaisrakul, Parawee, Lumjiaktase, Putthapoom, Kietdumrongwong, Pongtorn, Chuatrisorn, Ittiporn, Chatsangjaroen, Pongsan, Phanuphak, Nittaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840162/
https://www.ncbi.nlm.nih.gov/pubmed/36641523
http://dx.doi.org/10.1038/s41598-023-28101-5
_version_ 1784869583880978432
author Chevaisrakul, Parawee
Lumjiaktase, Putthapoom
Kietdumrongwong, Pongtorn
Chuatrisorn, Ittiporn
Chatsangjaroen, Pongsan
Phanuphak, Nittaya
author_facet Chevaisrakul, Parawee
Lumjiaktase, Putthapoom
Kietdumrongwong, Pongtorn
Chuatrisorn, Ittiporn
Chatsangjaroen, Pongsan
Phanuphak, Nittaya
author_sort Chevaisrakul, Parawee
collection PubMed
description The death rate from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in 2022 was lower than the death rate in 2021, when the infection rate increased. Hybrid immunity provided by a combination of vaccination and infection, including asymptomatic infection, may confer effective protection against death. We explored the combined effect of asymptomatic infection and hybrid immunity by studying T-cell and antibody responses against SARS-CoV-2 among individuals treated in home health care services 6 months after SARS-CoV-2 exposure. Asymptomatic SARS-CoV-2 infection was demonstrated in 24.4% of close contacts. The levels of immunity were not different between patients and close contacts. Anti-RBD IgG against SARS-CoV-2 increased in a dose-dependent manner with the number of vaccine doses. Interestingly, the T-cell response decreased soon after a booster dose of vaccine. Asymptomatic SARS-CoV-2 infection could not enhance immunity against SARS-CoV-2 among vaccinated close contacts. Full vaccination was crucial to provide hybrid immunity. However, when designing vaccine strategies, T-cell exhaustion after multiple vaccinations should be considered.
format Online
Article
Text
id pubmed-9840162
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98401622023-01-16 Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program Chevaisrakul, Parawee Lumjiaktase, Putthapoom Kietdumrongwong, Pongtorn Chuatrisorn, Ittiporn Chatsangjaroen, Pongsan Phanuphak, Nittaya Sci Rep Article The death rate from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in 2022 was lower than the death rate in 2021, when the infection rate increased. Hybrid immunity provided by a combination of vaccination and infection, including asymptomatic infection, may confer effective protection against death. We explored the combined effect of asymptomatic infection and hybrid immunity by studying T-cell and antibody responses against SARS-CoV-2 among individuals treated in home health care services 6 months after SARS-CoV-2 exposure. Asymptomatic SARS-CoV-2 infection was demonstrated in 24.4% of close contacts. The levels of immunity were not different between patients and close contacts. Anti-RBD IgG against SARS-CoV-2 increased in a dose-dependent manner with the number of vaccine doses. Interestingly, the T-cell response decreased soon after a booster dose of vaccine. Asymptomatic SARS-CoV-2 infection could not enhance immunity against SARS-CoV-2 among vaccinated close contacts. Full vaccination was crucial to provide hybrid immunity. However, when designing vaccine strategies, T-cell exhaustion after multiple vaccinations should be considered. Nature Publishing Group UK 2023-01-14 /pmc/articles/PMC9840162/ /pubmed/36641523 http://dx.doi.org/10.1038/s41598-023-28101-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Chevaisrakul, Parawee
Lumjiaktase, Putthapoom
Kietdumrongwong, Pongtorn
Chuatrisorn, Ittiporn
Chatsangjaroen, Pongsan
Phanuphak, Nittaya
Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program
title Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program
title_full Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program
title_fullStr Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program
title_full_unstemmed Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program
title_short Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program
title_sort hybrid and herd immunity 6 months after sars-cov-2 exposure among individuals from a community treatment program
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840162/
https://www.ncbi.nlm.nih.gov/pubmed/36641523
http://dx.doi.org/10.1038/s41598-023-28101-5
work_keys_str_mv AT chevaisrakulparawee hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram
AT lumjiaktaseputthapoom hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram
AT kietdumrongwongpongtorn hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram
AT chuatrisornittiporn hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram
AT chatsangjaroenpongsan hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram
AT phanuphaknittaya hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram